Tandem Diabetes Care Files 8-K Report

TL;DR

Tandem Diabetes Care filed an 8-K, but details are scarce.

AI Summary

On May 16, 2025, Tandem Diabetes Care, Inc. filed an 8-K report to disclose other events. The filing does not contain specific details about the nature of these events, dollar amounts, or definitive dates beyond the report filing date.

Why It Matters

This filing indicates that Tandem Diabetes Care has reported significant events to the SEC, which could impact investors' understanding of the company's current status.

Risk Assessment

Risk Level: low — The filing is a standard 8-K report of other events without specific material disclosures, making the immediate risk low.

Key Players & Entities

• Tandem Diabetes Care, Inc. (company) — Registrant
• May 16, 2025 (date) — Date of earliest event reported
• 12400 High Bluff Drive (location) — Principal executive offices address
• San Diego (location) — City of principal executive offices
• California (location) — State of principal executive offices

FAQ

From the Filing

0001438133-25-000091.txt : 20250520 0001438133-25-000091.hdr.sgml : 20250520 20250519182817 ACCESSION NUMBER: 0001438133-25-000091 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20250516 ITEM INFORMATION: Other Events FILED AS OF DATE: 20250520 DATE AS OF CHANGE: 20250519 FILER: COMPANY DATA: COMPANY CONFORMED NAME: TANDEM DIABETES CARE INC CENTRAL INDEX KEY: 0001438133 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services EIN: 204327508 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36189 FILM NUMBER: 25965499 BUSINESS ADDRESS: STREET 1: 12400 HIGH BLUFF DRIVE CITY: San Diego STATE: CA ZIP: 92130 BUSINESS PHONE: 858-366-6900 MAIL ADDRESS: STREET 1: 12400 HIGH BLUFF DRIVE CITY: San Diego STATE: CA ZIP: 92130 8-K 1 tndm-20250516.htm 8-K tndm-20250516 0001438133 FALSE 0001438133 2025-05-16 2025-05-16   UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________ FORM 8-K ____________________________ CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2025 ____________________________ Tandem Diabetes Care, Inc. (Exact name of registrant as specified in its charter) ____________________________ Delaware 001-36189 20-4327508 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer  Identification No.) 12400 High Bluff Drive 92130 San Diego California (Zip Code) (Address of principal executive offices) Registrant’s telephone number, including area code: ( 858 )  366-6900 N/A (Former name or former address, if changed since last report) ____________________________ Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐     Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of Each Class Trading Symbol Name of Each Exchange on Which Registered Common Stock, par value $0.001 per share TNDM NASDAQ Global Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company  ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐ ____________________________ Item 8.01 Other Events . On May 16, 2025, Tandem Diabetes Care, Inc. (the Company) received CE mark approval for the Tandem Mobi insulin delivery system with Control-IQ+ technology. The Company intends to pursue additional regulatory and pre-commercial activities, such as securing in-country registrations and reimbursement for Tandem Mobi in EU markets, with plans to begin EU commercial launches by the end of 2025. Forward-Looking Statements This report contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934